UNSPSC 51122600: Combination antilipemic agents

This classification denotes combination drugs that lower the levels of certain lipids (or alcohol-ether-soluble constituents of protoplasm) in the blood, such as fats, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids, and which therefore treat hyperlipidemia, hence the term ANTILIPEMIC AGENTS. Typical combination antilipemic agent constituents are aspirin, cholestyramine, ezetimibe, lovastatin, and niacin.

UNSPSC 51122600 Combination antilipemic agents is a Class code that covers pharmaceutical supplies state and local governments procure for emergency medical services, public health programs, and multistate cooperative purchasing initiatives. Recent solicitations show activity substantially broader than the code's nominal scope — state and local buyers are acquiring individual medications for emergency response, conducting market intelligence on direct-to-manufacturer pharmacy models, and establishing generic pharmaceutical contracts through cooperative purchasing vehicles. The City of Tampa's sealed-bid procurement for Advanced Life Support Medications (IFB 26P00188, due April 8, 2026) exemplifies the narrow product-specific purchases under this code: Tampa Fire Rescue required Labetalol, Epinephrine, Adenosine, and Diltiazem injections and vials, with a $40,000 estimated contract value and a five-percent Small Local Business Enterprise bid discount. Issuing bodies include city fire departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions.

Geographic activity centers on Florida and Minnesota, with exploratory procurement underway in Texas. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal for generic multi-source pharmaceuticals and OTC products (RFP S1070000015802, due March 26, 2026) covering participating state and local facilities across Minnesota and Oregon, with contract effectiveness set for July 1, 2026. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013, due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer pharmacy relationships, signaling preliminary exploration of a Therapeutic Pharmacy Initiative program before formal solicitation. Recent opportunities show varying procurement mechanics — firm-price one-year contracts with renewal options (Tampa), two-year cooperative agreements with administrative fee structures and performance penalties (MMCAP), and early-stage market intelligence gathering (Texas HHS).